Search

We observed 66 patients with chronic pyelonephritis in the exacerbation phase who received standard treatment with antibacterial drugs based on susceptibility of causative agents. All patients were randomly divided into two groups. Patients of study group have received phytodrug prolit super septo 2 capsules 2 times a day for 4 weeks in addition to standard treatment. Patients of control group have received standard therapy only. As a result of treatment, high effectiveness of therapy and reduction of length of treatment was noted in the study group. There were no subjective symptoms of disease in all patients at the end of treatment. Reduction of leykocituria and bacteriuria, normalization of body temperature, normalization of blood analysis and restoration of intrarenal blood flow were observed earlier in the study group compared with the control group. Recurrence of disease 3 months after end of treatment was not revealed in none of the patient in the study group, whereas it was noted in 14% of patients in the control group.

The study was aimed to the evaluation of the efficacy of prolit in patients with urolithiasis and localization of stone in the ureter. 225 patients with various localization of solitary ureteral calculi ranged from 0.4 to 0.7 cm were under observation. Depending on the treatment, the patients were divided into two groups. The study group (n = 175) has received prolit for 30-40 days, control group (n = 50) has received standard therapy. As a result of treatment, spontaneous discharge of ureteral stone was registered in 158 (90.3%) patients of study group and only in 21 (42%) patients of control group. Renal colics during treatment were recorded four times more often among patients of control group. The intensity of pain in patients receiving prolit was less pronounced.

A total of 76 patients with chronic abacterial prostatitis (CAP) in combination with erectile dysfunction were divided into two groups. Clinical symptoms of CAP and severity of erectile dysfunction were the same in both groups. Patients of the study group (n = 36) received pathogenetic treatment (vitaprost plus physiotherapy) and impase. The control group (n = 40) received vitaprost and physiotherapy. The results of the treatment showed that impase addition to combined treatment of CAP patients with erectile dysfunction significantly improves erectile function: 80.6% patients given impase raised their score by International Index of Erectile Function Scale to normal (26 points and higher). Impase efficacy increased with prolongation of the treatment from 4 to 12 weeks.

Our study of efficacy of Prolit-septo phytotherapy following extracorporeal shock-wave lithotripsy (ESWLT) in patients with nephrolithiasis has demonstrated that Prolit-septo noticeably reduces the time of evacuation from the urinary tract of the destructed stone fragments as well as renal colic incidence and renal inflammation exacerbation.

Pharmacotherapy of prostatic adenoma is based in present-day practice primarily on two basic groups of medicines--inhibitors of 5alpha-reductase and blockers of alphal-adrenoreceptors. Our trial included 98 patients with prostatic adenoma aged 59-79 years given combined treatment with finasteride (inhibitor of 5alpha-reductase) made in Hungary (prosteride, Gedeon Richter) and an uroselective blocker of alpha1-adrenoreceptors sonisin (Gedeon Richter, Hungary). Prosteride was given for 12 months, sonisine--for the first 6 months of combined treatment. Positive results were achieved in 97 (99%) of 98 patients. After 12-month combined treatment symptoms of the disease reduced by IPSS from 17.9 +/- 1.8 to 3.9 +/- 0.9 points, Qmax rose from 8.8 +/- 0.3 to 14.6 +/- 0.3, residual urine volume diminished from 91.7 +/- 8.5 to 31.7 +/- 4.4, the size of the prostate reduced from 72.4 +/- 2.9 to 50.6 +/- 3.7, quality of life improved 2-fold. Combined administration of finasteride (prosteride) and alpha1-adrenoblocker tamsulosine (sonisine) meet three principles of pharmacotherapy of prostatic adenoma: prevents progression of the disease and surgical treatment, relieves symptoms and improves quality of life.

Phytotherapy with prolit was given to 95 patients with ureteroliths (size of the concrrements 0.4-0.6 cm). A 40-day treatment resulted in elimination of the concrements from the ureter in 89 (93.7%) patients. Prolit had a positive action on metabolism in urolithiasis patients: lowered hypercalciuria, uric acid in the blood, oxalates and uric acid in urine. This is important for prevention of recurrent lithogenesis which for 3 years after the treatment occurred only in 4 (4.2%) patients.

Optical coherence tomography (OCT) was tested in diagnosis of bladder cancer (BC) in 100 BC suspects. This method showed higher sensitivity (by 16%) in diagnosis of BC compared to standard cystoscopy as it more presicely identified squamous intraepithelial and noninvasive tumors. The analysis of OCT images was made with a noval computer program of filtration and color overlay. This improved quality of the image allowed verification or rejection of BC, its localization on urinary bladder wall.

Efficacy and safety of a new bioregulatory peptide vitaprost forte was studied in 30 patients with prostatic adenoma. It is shown that this drug relieves clinical symptoms of the disease, improves quality of life, uroflowmetric parameters, reduces the size of the prostatic gland. Vitaprost forte is more effective in patients with prostatic adenoma combined with chronic prostatitis.

Finasteride effect before transurethral resection (TUR) of the prostatic gland was studied in 88 patients with prostatic adenoma (PA). Forty seven patients received prosteride (Gedeon Richter), forty one patients - proscar (MSD) in a dose 5 mg/day for 3 months. Finasteride reduced blood flow in prostatic tissue, density of the vascular plexus, epithelium/stroma coefficient from 1.26 to 0.84. This decreased intraoperative blood loss, postoperative hematuria, TUR duration, postoperative rehabilitation, number of early and late TUR complications.

We studied efficacy of a new cytomedine drug--vitaprost--in 98 patients with chronic abacterial prostatitis. Vitaprost was found to relieve symptoms of the disease, improved blood flow in the prostate, normalized blood rheology and immunological indices, increased mobility of spermatozoa in ejaculate.

Prostatilen was used in 1115 patients with chronic pyelonephritis and prostatitis. It is shown that prostatilen has a corrective effect on hemocoagulation and immunity disorders, restores microcirculation, suppresses inflammation in the kidney and prostate. Thus, prostatilen is a pathogenetically sound drug for treatment in urogenital inflammation while in chronic prostatitis it can be used as a basic therapy.

A long-term proskar (finasterid, MSD) treatment was given to 428 patients with benign prostatic hyperplasia (BPH). The response was achieved in 93.8-95.8% patients. The duration of the course should be at least 12 months. Side effects were rare: libido, erection, ejaculate volume diminished in 5.1, 5.6 and 4.2% patients, respectively. 20 patients were operated on after proskar therapy. Such pretreatment reduced glandular prostatic tissue.

Combined treatment including alpha-1a-adrenoreceptor blocker tamsulosine was given to 92 patients with chronic prostatitis having marked urination disorders (IPSS score 12.1 +/- 2.4). The response was achieved in 98.9% of cases. There was attenuation of the urination symptoms, speeding up of the maximal urine flow, decreased amount of the residual urine. It is recommended to add alpha-1-adrenoreceptors to combined treatment of chronic prostatitis patients with urination disorders.